Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMO-103 in advanced solid tumours
NCT04808362Phase 2Terminated
- Sponsor
- Peptomyc
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OMO-103 in solid tumor (advanced stage), pancreatic cancer (PC), colorectal cancer (CRC) and 2 more, sponsored by Peptomyc. Primary endpoint: Safety and Tolerability. Started Apr 2021; status: terminated.
02
Drugs
OMO-103
03
Conditions
solid tumor (advanced stage)pancreatic cancer (PC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04808362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808362.